Series B funding round for Engrail Therapeutics raising $160M in March 2024
Series B funding round for Engrail Therapeutics raising $160M in March 2024
| Investor | Firm Type | Partner |
|---|
| Private | — |
ForbionLEAD | Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Venture Capital | — |
| Angel | Ed Mathers |
This company has completed 3 funding rounds. Current round is highlighted.
Total Raised
$224M
Top Valuation
-
Engrail Therapeutics raised $160M in a Series B round.
The round was announced on 03/01/24.
The round was led by Forbion, Stacie Weninger, Tiba Aynechi.